MedTrace Logo

Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)

NCT04351919 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-08-28

No results posted yet for this study

Summary

The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomatic patients with ou without co-morbidities

Conditions

  • Patients With COVID19

Interventions

DRUG

Hydroxychloroquine

400mg per day during 10 days

DRUG

Azithromycin

500 mg per day during 5 days

Sponsors & Collaborators

  • Eshmoun Clinical Research Center

    collaborator NETWORK

  • Dacima Consulting

    collaborator OTHER

  • Abderrahmane Mami Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-05
Primary Completion
2020-07-15
Completion
2020-07-15

Countries

  • Tunisia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04351919 on ClinicalTrials.gov